• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • NORTH AMERICA EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • NORTH AMERICA EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Cannabis Market
Cannabis News
Cannabis Stocks
  • Cannabis Market
  • Cannabis News
  • Cannabis Stocks
cannabis investing

Emerald Health Therapeutics Launches New Product Line

Bryan Mc Govern
Jul. 02, 2019 09:01AM PST
Cannabis Investing News

Emerald Health Therapeutics announced the introduction of a new health supplement product line, with no cannabis in it, through its joint venture with Emerald Health Naturals.

Emerald Health Therapeutics (TSXV:EMH,OTCQX:EMHTF) announced the introduction of a new health supplement product line, with no cannabis in it, through its joint venture with Emerald Health Naturals (EHN).

As quoted in the press release:

The Endo product line includes Endo Brain, Endo Sleep, Endo Calm, Endo Bliss, Endo Inflame and Endo Omega, and are intended to foster overall health and wellness and potentially enhance the body’s response to conditions such as stress, anxiety, restless sleep, inflammation and pain. These products feature PhytoCann Complex, a proprietary formulation consisting of non-psychoactive, plant-based bioactive compounds that support the body’s endocannabinoid system. All products are manufactured according to strict pharmaceutical quality standards.

“Apart from our strongly positioned presence in the cannabis space, the Endo product launch allows us to uniquely expand Emerald’s business opportunities by accessing natural health product, pharmacy, and grocery stores, channels unavailable to cannabis products, with our non-cannabis supplements,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “We see non-cannabis endocannabinoid-supporting products as the creation of a distinct and significant new natural health product category. Furthermore, our proprietary active ingredient, Phytocann Complex, offers the potential to be incorporated into an array of supplements, foods, and beverages.”

Eighty percent of Canadians consume natural health products each year. Emerald aims to widely offer its Endo products in retail outlets and is targeting more than 1,000 natural health product stores, pharmacies and grocery stores in Canada by the end of 2019.

Click here to read the full press release.

cannabis investing tsxv:emh canada emerald health therapeutics avtar dhillon
The Conversation (0)

Go Deeper

AI Powered
Person touching a cannabis plant; Australia map in flag colours.

ASX Cannabis Stocks: 10 Biggest Companies in 2025

A colorful brain illustrating brain on pyschedelics.

Psychedelics Stocks to Watch

Latest News

More News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Cannabis Investing News Stocks

extractX

extractX (None)
More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES